Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 still in force?

Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is currently in force.

When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 take effect?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 was first recorded in 2017.

How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 have?

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 contains 2 sections.

Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017?

The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is published at lom.agc.gov.my.

/akn/my/act/pua/2017/130

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017

The full official text, structured for quick navigation. Copy any provision or jump straight to a section.

Open source PDF

Type: P.U. (A)
Status: In force
Enacted: 2017
Sections: 2

Quick answer

About this p.u. (a)

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is Malaysia P.U. (A), cited as P.U. (A) 130 2017, currently marked in force and first recorded in 2017.

Opening note

Preamble

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama

Seksyen 1

Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) 2017.

Seksyen 2

Pindaan Jadual Pertama

(a)

dalam Senarai Racun—

(i)

dengan memasukkan selepas butiran “Bencyclane; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Bahagian I

Part I

Bahagian II

Part II

Exempt

Group A

Group B

Group C

Group D

“Bendamustine

All preparations”;

(ii)

dengan memasukkan selepas butiran “Celecoxib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ceritinib

All preparations”;

(iii)

dengan memasukkan selepas butiran “Crizotinib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Crofelemer

All preparations”;

(iv)

dengan memasukkan selepas butiran “Dabigatran” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Daclatasvir

All preparations”;

(v)

dengan menggantikan butiran “Dextrophan; its salts” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dextrorphan; its salts

All preparations”;

(vi)

dengan memasukkan selepas butiran “Drotrecogin alfa (Recombinant human activated Protein C)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Dulaglutide

All preparations”;

(vii)

dengan memasukkan selepas butiran “Elaterin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Elosulfase

All preparations”;

(viii)

dengan memasukkan selepas butiran “Fazadinium bromide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Febuxostat

All preparations”;

(ix)

dengan memotong butiran “Febantel” dan butir-butir yang berhubungan dengannya;

(x)

dengan memasukkan selepas butiran “Idarubicin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Idelalisib

All preparations”;

(xi)

dengan memasukkan selepas butiran “Lead tetraethyl” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ledipasvir

All preparations”;

(xii)

dengan memasukkan selepas butiran “Nepafenac” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Netupitant

All preparations”;

(xiii)

dengan memasukkan selepas butiran “Nimorazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Nintedanib

All preparations”;

(xiv)

dengan memotong butiran “Praziquantel” dan butir-butir yang berhubungan dengannya;

(xv)

dengan memasukkan selepas butiran “Ruxolitinib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Sacubitril

All preparations”;

(xvi)

dengan memasukkan selepas butiran “Secnidazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Secukinumab

All preparations”;

(xvii)

dalam butiran “Ulipristal”, dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Ulipristal

All preparations”; dan 8

(xviii)

dengan memasukkan selepas butiran “Viloxazine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

Exempt

Group A

Group B

Group C

Group D

“Vismodegib

All preparations”; dan

(b)

dalam Lampiran kepada Senarai Racun—

(i)

dalam senarai “Anthelmintics:”, dengan memotong butiran “Febantel” dan “Praziquantel”;

(ii)

dalam senarai “Antidiabetics:”, dengan memasukkan selepas butiran “Dapagliflozin” butiran “Dulaglutide”;

(iii)

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

(A)

dengan memasukkan selepas butiran “Belimumab” butiran “Bendamustine”;

(B)

dengan memasukkan selepas butiran “Carmustine; its salts” butiran “Ceritinib”;

(C)

dengan memasukkan selepas butiran “Idarubicin” butiran “Idelalisib”;

(D)

dengan memasukkan selepas butiran “Nilotinib” butiran “Nintedanib”;

(E)

dengan memasukkan selepas butiran “Ruxolitinib” butiran “Secukinumab”; dan

(F)

dengan memasukkan selepas butiran “Vinca, alkaloids of, including synthetic preparations” butiran “Vismodegib”;

(iv)

dalam senarai “Antitussive:”, dengan menggantikan butiran “Destrophan; its salts” dengan butiran “Dextrorphan; its salts”;

(v)

dalam senarai “Antiviral agents:”—

(A)

dengan memasukkan selepas butiran “Clevudine” butiran “Daclatasvir”; dan

(B)

dengan memasukkan selepas butiran “Lamivudine” butiran “Ledipasvir;

(vi)

dalam senarai “Cardio drugs:”, dengan memasukkan selepas butiran “Quinidine; its salts” butiran “Sacubitril”;

(vii)

dalam senarai “Uricosuric agents:”, dengan memasukkan selepas butiran “Colchicine” butiran “Febuxostat”; dan

(viii)

dalam senarai “Miscellaneous:”—

(A)

dengan memasukkan selepas butiran “Creosote, obtained from wood” butiran “Crofelemer”;

(B)

dengan memasukkan selepas butiran “Elaterin” butiran “Elosulfase”; dan

(C)

dengan memasukkan selepas butiran “Nedocromil sodium” butiran “Netupitant”.

Dibuat 17 Mac 2017

[KK(R)608(14); PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM

Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2017

Opening note

Preamble

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) Order 2017. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule—

(a)

in the Poisons List—

(i)

by inserting after the item “Bencyclane; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Bendamustine

All preparations”;

(ii)

by inserting after the item “Celecoxib” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ceritinib

All preparations”;

(iii)

by inserting after the item “Crizotinib” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Crofelemer

All preparations”;

(iv)

by inserting after the item “Dabigatran” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Daclatasvir

All preparations”;

(v)

by substituting for the item “Dextrophan; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dextrorphan; its salts

All preparations”;

(vi)

by inserting after the item “Drotrecogin alfa (Recombinant human activated Protein C)” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Dulaglutide

All preparations”;

(vii)

by inserting after the item “Elaterin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Elosulfase

All preparations”;

(viii)

by inserting after the item “Fazadinium bromide” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Febuxostat

All preparations”;

(ix)

by deleting the item “Febantel” and the particulars relating to it;

(x)

by inserting after the item “Idarubicin” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Idelalisib

All preparations”;

(xi)

by inserting after the item “Lead tetraethyl” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Ledipasvir

All preparations”;

(xii)

by inserting after the item “Nepafenac” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Netupitant

All preparations”;

(xiii)

by inserting after the item “Nimorazole” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Nintedanib

All preparations”;

(xiv)

by deleting the item “Praziquantel” and the particulars relating to it;

(xv)

by inserting after the item “Ruxolitinib” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Sacubitril

All preparations”;

(xvi)

by inserting after the item “Secnidazole” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Secukinumab

All preparations”;

(xvii)

in the item “Ulipristal”, by substituting for the particulars relating to it the following particulars:

Names

Exempt

Group A

Group B

Group C

Group D

“Ulipristal

All preparations”; and

(xviii)

by inserting after the item “Viloxazine; its salts” and the particulars relating to it the following item:

Names

Exempt

Group A

Group B

Group C

Group D

“Vismodegib

All preparations”; and

(b)

in the Appendix to the Poisons List—

(i)

under the list of “Anthelmintics:”, by deleting the items “Febantel” and “Praziquantel”;

(ii)

under the list of “Antidiabetics:”, by inserting after the item “Dapagliflozin” the item “Dulaglutide”;

(iii)

under the list of “Antineoplastic agents and Immunosuppressants:”—

(A)

by inserting after the item “Belimumab” the item “Bendamustine”;

(B)

by inserting after the item “Carmustine; its salts” the item “Ceritinib”;

(C)

by inserting after the item “Idarubicin” the item “Idelalisib”;

(D)

by inserting after the item “Nilotinib” the item “Nintedanib”;

(E)

by inserting after the item “Ruxolitinib” the item “Secukinumab”; and

(F)

by inserting after the item “Vinca, alkaloids of, including synthetic preparations” the item “Vismodegib”;

(iv)

under the list of “Antitussive:”, by substituting for the item “Destrophan; its salts” the item “Dextrorphan; its salts”;

(v)

under the list of “Antiviral agents:”—

(A)

by inserting after the item “Clevudine” the item “Daclatasvir”; and

(B)

by inserting after the item “Lamivudine” the item “Ledipasvir”;

(vi)

under the list of “Cardio Drugs:”, by inserting after the item “Quinidine, its salts” the item “Sacubitril”;

(vii)

under the list of “Uricosuric agents:”, by inserting after the item “Colchicine” the item “Febuxostat”; and

(viii)

under the list of “Miscellaneous:”—

(A)

by inserting after the item “Creosote, obtained from wood” the item “Crofelemer”;

(B)

by inserting after the item “Elaterin” the item “Elosulfase”; and

(C)

by inserting after the item “Nedocromil sodium” the item “Netupitant”.

Made 17 March 2017

[KK(R)608(14); PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM

Minister of Health

Common questions

What is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is Malaysia P.U. (A), cited as P.U. (A) 130 2017, currently marked in force and first recorded in 2017.
Is PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 still in force?: Yes — PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is currently in force.
When did PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 take effect?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 was first recorded in 2017.
How many sections does PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 have?: PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 contains 2 sections.
Where can I read the official version of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017?: The official text of PERINTAH RACUN (PINDAAN SENARAI RACUN) 2017 is published at lom.agc.gov.my.